Company Growth (employees)
Cytori Therapeutics was founded in 1996 and is headquartered in San Diego, US
Cytori Therapeutics Office Locations
Cytori Therapeutics has offices in San Diego, Flintshire and Minato-ku
San Diego, US (HQ)
3020 Callan Rd
Cytori Therapeutics Data and Metrics
Cytori Therapeutics Financial Metrics
Cytori Therapeutics's revenue was reported to be $4.7 m in FY, 2016 which is a 4% decrease from the previous period.
USD
Revenue (FY, 2016) | 4.7 m |
Revenue growth (FY, 2015 - FY, 2016), % | (4%) |
Gross profit (FY, 2016) | 1.9 m |
Gross profit margin (FY, 2016), % | 42% |
Net income (FY, 2016) | (22 m) |
EBIT (FY, 2016) | (19.7 m) |
Market capitalization (20-Jul-2017) | 36.4 m |
Closing share price (20-Jul-2017) | 1.1 |
Cash (31-Dec-2016) | 12.6 m |
Cytori Therapeutics's current market capitalization is $36.4 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 7.1 m | 5 m | 4.8 m | 4.7 m |
Revenue growth, % | (30%) | (2%) | (4%) | |
Cost of goods sold | 3.4 m | 2.9 m | 3.2 m | 2.7 m |
Gross profit | 3.7 m | 2 m | 1.7 m | 1.9 m |
Gross profit Margin, % | 52% | 41% | 34% | 42% |
Sales and marketing expense | 9 m | 6.4 m | 2.7 m | 3.6 m |
R&D expense | 17.1 m | 15.1 m | 19 m | 16.2 m |
General and administrative expense | 16 m | 16 m | 9.8 m | 8.6 m |
Operating expense total | 39.5 m | 37.1 m | 23.8 m | 28.4 m |
EBIT | (30.7 m) | (32.4 m) | (15.3 m) | (19.7 m) |
EBIT margin, % | (431%) | (655%) | (316%) | (423%) |
Interest expense | 3.4 m | 4.4 m | 3.4 m | 2.6 m |
Interest income | 4 k | 6 k | 9 k | 19 k |
Net Income | (26.2 m) | (37.4 m) | (18.7 m) | (22 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 15.5 m | 14.6 m | 14.3 m | 12.6 m |
Inventories | 3.7 m | |||
Current Assets | 24.6 m | 21.7 m | 21.2 m | 18.7 m |
PP&E | 1.1 m | 1.6 m | 1.6 m | 1.2 m |
Goodwill | 3.9 m | 3.9 m | 3.9 m | 3.9 m |
Total Assets | 42.1 m | 38.7 m | 37.7 m | 34.6 m |
Accounts Payable | 6.1 m | 5.5 m | 6.7 m | 5.9 m |
Current Liabilities | 14.9 m | 15.9 m | 8.4 m | 12.5 m |
Total Liabilities | 23.6 m | |||
Additional Paid-in Capital | 303.7 m | 331.8 m | 368 m | 388.8 m |
Retained Earnings | (300.9 m) | (338.3 m) | (357 m) | (379.1 m) |
Total Equity | 3.1 m | 11 m | ||
Financial Leverage | 13.4 x | 3.2 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (26.2 m) | (37.4 m) | (18.7 m) | (22 m) |
Depreciation and Amortization | 1.6 m | 779 k | 1.1 m | 1.2 m |
Accounts Receivable | (1.2 m) | 2.1 m | 328 k | (179 k) |
Inventories | (459 k) | (815 k) | 490 k | 471 k |
Accounts Payable | (409 k) | (1.1 m) | 1 m | (673 k) |
Cash From Operating Activities | (34.6 m) | (30.3 m) | (20.5 m) | (19.5 m) |
Purchases of PP&E | (519 k) | (764 k) | (611 k) | (67 k) |
Cash From Investing Activities | 3.7 m | (1.3 m) | (613 k) | 64 k |
Dividends Paid | (75 k) | |||
Cash From Financing Activities | 20.8 m | 30.9 m | 20.8 m | 17.6 m |
Interest Paid | 2.3 m | 2.6 m | 2 m | 1.6 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 3.2 x |
